We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
10.1161/CIRCULATIONAHA.118.036811
Journal article
Circulation
27/11/2018
138
2576 - 2578
cardiovascular diseases, outcome measures, pharmacotherapy, type 2 diabetes mellitus, Cardiovascular Diseases, Drug Administration Schedule, Exenatide, Glucagon-Like Peptide-1 Receptor, Glycated Hemoglobin A, Humans, Placebo Effect, Proportional Hazards Models, Treatment Outcome